Combined treatment with thymosin-α1 and low dose interferon-α after dacarbazine in advanced melanoma

被引:25
|
作者
Rasi, G [1 ]
Terzoli, E
Izzo, F
Pierimarchi, P
Ranuzzi, M
Sinibaldi-Vallebona, P
Tuthill, C
Garaci, E
机构
[1] CNR, Ist Med Sperimentale, I-00137 Rome, Italy
[2] Univ Rome Tor Vergata, Rome, Italy
[3] Ist Regina Elena, I-00161 Rome, Italy
[4] SciClone Pharmaceut Inc, San Mateo, CA USA
关键词
advanced melanoma; combination treatment; DTIC; interferon; thymosin-alpha; 1;
D O I
10.1097/00008390-200010020-00012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
[No abstract available]
引用
收藏
页码:189 / 192
页数:4
相关论文
共 50 条
  • [21] Cisplatin, dacarbazine, fotemustine, and interferon-α2B in advanced melanoma:: A phase II study of Italian Melanoma Study Group (IMSG)
    Daponte, A
    Comella, P
    Cellerino, R
    De Lena, M
    Brandi, M
    Marini, G
    Failla, G
    De Vita, F
    Rivellini, F
    Gravina, A
    Mozzillo, N
    Caraco, C
    Comella, G
    ANNALS OF ONCOLOGY, 1998, 9 : 117 - 117
  • [22] Intermediate dose recombinant interferon-α as second-line treatment for patients with recurrent cutaneous melanoma who were pretreated with low dose interferon
    Ascierto, PA
    Daponte, A
    Parasole, R
    Perrone, F
    Caracò, C
    Melucci, MT
    Palmieri, G
    Napolitano, M
    Mozzillo, N
    Castello, G
    CANCER, 2000, 89 (07) : 1490 - 1494
  • [23] Preliminary experience with high-dose cisplatin, reduced glutathione and natural interferon-α in dacarbazine-resistant malignant melanoma
    Bajetta, E
    Rimassa, L
    Carnaghi, C
    Del Vecchio, M
    Celio, L
    Cassata, A
    TUMORI, 1998, 84 (01) : 48 - 51
  • [24] Long-term survival benefit after adjuvant treatment of cutaneous melanoma with dacarbazine and low dose natural interferon alpha:: A controlled, randomised multicentre trial
    Stadler, Rudolf
    Luger, Thomas
    Bieber, Thomas
    Koehler, Ulrike
    Linse, Ruthild
    Technau, Kristin
    Schubert, Roland
    Schroth, Katja
    Vakilzadeh, Feredoun
    Volkenandt, Matthias
    Gollnick, Harald
    Von Eick, Harald
    Thoren, Fredrik
    Strannegard, Orjan
    ACTA ONCOLOGICA, 2006, 45 (04) : 389 - 399
  • [25] Low doses interferon-α in the treatment of high-risk cutaneous melanoma
    Ascierto, PA
    Palmieri, G
    Strazzullo, M
    Daponte, A
    Botti, G
    Satriano, SMR
    Motti, ML
    Mozzillo, N
    Castello, G
    ANNALS OF ONCOLOGY, 2000, 11 (04) : 487 - 490
  • [26] EXPERIENCE WITH INTERFERON-ALPHA-2B COMBINED WITH DACARBAZINE IN THE TREATMENT OF METASTATIC MALIGNANT-MELANOMA
    FALKSON, CI
    MEDICAL ONCOLOGY, 1995, 12 (01): : 35 - 40
  • [27] COMBINED TREATMENT OF METASTATIC MELANOMA WITH DACARBAZINE AND RECOMBINANT ALPHA-2A INTERFERON - RESULTS OF A MULTICENTRIC STUDY
    AVRIL, MF
    BEERBLOCK, K
    DRENO, B
    DELAUNAY, M
    BONERANDI, JJ
    GUILLAUME, JC
    SOUTEYRAND, P
    KALIS, B
    CHEVRANTBRETON, J
    VERRET, J
    FOLLET, M
    GODEFROY, W
    BULLETIN DU CANCER, 1990, 77 (12) : 1183 - 1191
  • [28] Combination low-dose lymphoblastoid interferon and thymosin alpha(1) therapy in the treatment of chronic hepatitis B
    Rasi, G
    Mutchnick, MG
    DiVirgilio, D
    SinibaldiVallebona, P
    Pierimarchi, P
    Colella, F
    Favalli, C
    Garaci, E
    JOURNAL OF VIRAL HEPATITIS, 1996, 3 (04) : 191 - 196
  • [29] Systemic Combined Chemotherapy with Low Dose of 5-Fluorouracil, Cisplatin, and Interferon-α for Advanced Hepatocellular Carcinoma: A Pilot Study
    Yasuji Komorizono
    Kazunori Kohara
    Makoto Oketani
    Masahiko Maeda
    Toshihiko Shibathou
    Shuhou Shigenobu
    Yasusi Hiramine
    Naruhiro Yamasaki
    Takushi Arima
    Ishibashi Kazuaki
    Terukatsu Arima
    Digestive Diseases and Sciences, 2003, 48 : 877 - 881
  • [30] Systemic combined chemotherapy with low dose of 5-fluorouracil, cisplatin, and interferon-α for advanced hepatocellular carcinoma -: A pilot study
    Komorizono, Y
    Kohara, K
    Oketani, M
    Maeda, M
    Shibathou, T
    Shigenobu, S
    Hiramine, Y
    Yamasaki, N
    Arima, T
    Kazuaki, I
    Arima, T
    DIGESTIVE DISEASES AND SCIENCES, 2003, 48 (05) : 877 - 881